导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.69% | 1347/4773 |
| 近一周 | -1.95% | 949/5462 |
| 近一月 | 1.12% | 433/5421 |
| 近一季 | 1.01% | 591/5209 |
| 近半年 | -3.94% | 2371/4920 |
| 近一年 | 4.20% | 1771/4366 |
| 近两年 | 25.64% | 2471/2954 |
| 近三年 | 19.07% | 1503/2253 |
| 成立以来 | 63.29% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.05% 600/4961 |
-10.14% 4057/5312 |
- - |
- - |
| 2025 | 3.22% 3141/4813 |
-2.72% 2962/3635 |
2.47% 1548/4076 |
2.35% 3805/4524 |
1.17% 1488/4813 |
| 2024 | 16.67% 781/3463 |
7.98% 209/2808 |
2.20% 376/3014 |
8.22% 2760/3129 |
-2.31% 2039/3463 |
| 2023 | 4.93% 210/2656 |
4.77% 873/2280 |
0.79% 275/2385 |
3.87% 168/2515 |
-4.34% 967/2655 |
| 2022 | -1.52% 48/2207 |
1.76% 94/1919 |
-1.14% 1681/2016 |
-2.21% 32/2113 |
0.10% 1541/2208 |
| 2021 | 18.07% 218/1822 |
4.81% 136/1255 |
9.03% 590/1330 |
4.61% 332/1466 |
-1.22% 1336/1822 |
| 2020 | - - |
- - |
- - |
- - |
3.60% 901/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 易方达中证红利ETF联接发起式C VS. 长安沪深300非周期A(740101) |